Objectives: To collect specific literature on type Ib endoleak after aorto-iliac endografting for abdominal aortic aneurysm, reporting data on diagnosis, treatment, and follow-up results.
Introduction
Type I endoleak is defined as the persistent perfusion of the aneurysm sac from the proximal (type Ia) or distal (type Ib) edge of the endograft, following endovascular abdominal aneurysm repair (EVAR). 1 According to the guidelines of the Society for Vascular Surgery, 2 a type I endoleak is "linked to a continued risk of rupture." In fact, the type I endoleak represents the leading cause of late rupture after EVAR in a recent meta-analysis by Antoniou et al. 3 Type Ib endoleak (IbELs) is associated with large common iliac arteries (16-22 mm in diameter) 4 
or
Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy tortuous iliac axis. 5 Literature about IbEL is very scant. To the best of our knowledge, only few dedicated experiences are reported in literature regarding incidence, presentation, and treatment of iliac IbEL, and no studies are available about the difference between type Ia and IbEL in terms of aneurysm rupture risk.
The aim of this systematic review is to collect specific literature on IbEL after aorto-iliac endografting, reporting data on diagnosis, frequency, treatment options, and follow-up results.
Materials and methods

Search strategy
The scientific publications about IbEL after EVAR for abdominal aortic or iliac aneurysm were searched in PubMed, Web of Science and Scopus. Reference lists of articles were also scanned to add suitable studies. Literature in English language published until 3 November 2016 was considered. The research was conducted by two authors (CBM and PP) and, in case of controversies, a consensus was reached. Strings entered in search boxes were: in PubMed "endoleak AND (type I 6 
Study selection
Inclusion criteria were: (1) reporting on abdominal aortic aneurysm (AAA) or iliac aneurysm as primary diagnosis and (2) reporting on distal endoleak after aorto-iliac endografting (distal sealing zone in iliac artery). Case reports were included. Articles dealing with endografting in other arterial segments (e.g. thoracic, popliteal) or in the abdominal aorta without iliac endograft extension were excluded. Additional exclusion criteria were: aortic dissection, type Ia (proximal) EL, not-specified type I endoleak, use of multilayer flow modulator, previous aortic surgery without endografting, commentary, review, experimental or in vitro study, no full text availability. Eligibility of the study was assessed after reading of the full text by CBM and PP and controversies resolution. In case of studies containing duplicate data, only the most recent one was included.
Data extraction
Extracted data were classified in several categories: patient data (number, age, and gender), data on endovascular treatment (indication, endograft configuration and type, and adjunctive procedures), endoleak data (time of diagnosis, localization of the IbEL, associated endoleaks), reintervention data (type, description, complications, mortality), and follow-up data (length, reintervention, mortality).
The type of IbEL repair was classified in endovascular, hybrid, and surgical. All not-deducible data were reported as "not specified." Data were independently extracted by two vascular surgeons (CMB, PP) and incongruous data were solved together.
Results
Search results
The flowchart for the study selection is shown in Figure 1 . Overall, 11 studies were included in the systematic review, corresponding to five original articles and six case reports. No specific original articles on IbEL were found. Specific data on selected studies are reported in Table 1 .
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Patients and EVAR procedure Total number of included patients was 29. Patients' demographics are summarized in Table 1 . Details about configuration, type of deployed endograft, and adjunctive procedures are summarized in Table 2 .
Ib endoleaks
Total number of IbEL was 30. Specific data on endoleaks are reported in 
Treatment of IbEL
Specific data about endoleak management are shown in Table 3 . Treatment of IbEL was endovascular in 27 cases (90%): 7 embolizations of the internal iliac artery associated with endograft iliac extensions, 10 endograft iliac extensions, 8 embolizations without iliac extensions (four with n-Butyl 2 cyanoacrylate (n-BCA), two with Onyx (ev3 Inc., Irvine, CA), 1 with coils, 1 with n-BCA associated with coils), one Palmaz stent, one iliac branched endograft. A hybrid approach was performed in one case (3.3%, one aorto-uni-iliac endograft with contralateral iliac plug and femorofemoral sovrapubic bypass grafting). Open surgery was performed in two cases (6.6%, one aorto-bi-iliac bypass graft in emergency setting, one dacron bypass graft between the distal portion of endograft and the external iliac artery with ligation of the right internal iliac artery).
After repair of IbEL, buttock claudication occurred in two cases (6.7%) (after one coil embolization of the internal iliac artery followed by stentgraft extension, and one bypass graft from the leaking endograft to the external iliac artery associated with ligation of the internal iliac artery). Both cases of buttock claudication were reported as mild, and in one case the maximal walking distance improved after six months.
Early mortality (<1 month after endoleak treatment) occurred in two cases (3.4%): one after urgent open conversion for type Ia endoleak, the second for urosepsis followed by multiorgan failure three weeks after endovascular treatment of IbEL. 
Follow-up
The follow-up specifications are reported in Table 3 . Type IbEL persisted or reappeared in three cases (10%) after endovascular treatment (one embolization with n-BCA, one embolization with Onyx, one internal iliac embolization and extender cuff deployment). Two of these (2/3, 66.7%) underwent reintervention (the first with coil embolization of the internal iliac artery and subsequent endograft extension, the latter with an adjunctive iliac extension).
No additional deaths during follow-up were reported.
Discussion
The current systematic review includes 11 publications considering 29 patients with 30 IbEL after aorto-iliac endografting. To date, scientific literature about this specific topic is very scant. The analysis of the specific literature suggests that a type IbEL may occur essentially for two different causes: (i) an error during planning, or a technical inaccuracy during the procedure (e.g. insufficient endograft oversize, short sealing zone) or (ii) a progression of the aneurysmal disease.
During the preoperative planning, the measurements of iliac diameters, lengths, and the correct choice of suitable endograft components are essential to secure a durable distal sealing zone. Normally, an endoleak due to a planning error appears early after EVAR. 18 During the follow-up, the progression of the aneurysmal disease in the aorta and iliac arteries leads to dilatation of iliac sealing zones, which may favor type IbEL some years after intervention. Considering data from the current literature review, diagnosis of IbEL was intraoperative in about 20% (6/28), within six months in about 30% (8/28) and after six months from endograft implant in half of the cases (14/28).
The length and the diameter of the distal sealing zone are crucial for IbEL prevention. A length of at least 10 mm is recommended by most endograft instruction for use (Cook Zenith Alpha: >10 mm ). The exploitation of the longest available iliac landing zone seems to be the most effective method to prevent endograft bending and/or dislocation. The distal edge of the endograft should be deployed as close as possible to the hypogastric ostium, in order to obtain the maximum sealing length of common iliac artery. Considering the sealing zone diameter, an oversizing >15% is reported as recommended to prevent distal complication. 23 Kaladji et al. 24 reported a statistical significant increase of the common iliac artery diameter within two years after endograft deployment. However, the radial force and hemodynamic constraints of the endograft are not sufficient to explain such described iliac artery dilatation. 24 Iliac endografts with a diameter >24 mm (e.g. in case of bell-bottom technique) are associated with an increased risk of IbEL during mid-term follow-up 25, 26 and seems to be related with limb retraction at five years. 27 The angulation of iliac axis seems to play a role in type IbEL. Coulston et al. 5 reported that 33 iliac limbs with iliac complications (IbEL, dislocation, insufficient engagement, occlusion, and kinks) were associated with higher tortuosity index when compared with 240 not-complicated limbs. In this experience, no statistical significant difference was found between the three types of implanted endograft devices (Zenith Flex (Cook Medical, Bloomington, IN), Endurant II (Medtronic, Minneapolis, MN), and Excluder (W. L. Gore and Associates, Flagstaff, AZ)). In our opinion, the tortuosity may be considered as an indicator of iliac limb complication, even if further studies are necessary to find possible correlation with co-factors (diameter, length, thrombosis, calcification) and IbEL.
Also, an AAA with !65 mm diameter seems to be related with a higher risk of IbEL. 23 In fact, in this systematic review, the size of the AAA is reported in 7/29 cases (24%), and the diameter exceeds 65 mm in 5/7 cases (71%).
Focusing on endograft, about half of IbEL developed in "old generation" devices. Many of these endografts are actually out-of-commerce (e.g. Ancure, Guidant, Indianapolis, IN; AneuRx, Medtronic/AVE Inc., Santa Rosa, CA). It is likely that technology development and devices innovation led to a reduction of complication rate, including IbEL.
The treatment of an IbEL is generally considered easier in comparison with type Ia endoleak. The deployment of a distal endograft extension is a minimally invasive, simple, and quick procedure and, in case of uncovered and not-dilated common iliac artery, it generally repairs the endoleak. In case of unavailability of an adequate distal neck in the common iliac artery, an endograft extension into the external iliac artery is necessary in most cases. The embolization of the hypogastric artery is possible and its necessity should be considered according to the risk of type II endoleak (size and angulation of hypogastric artery, diameter of iliac bifurcation). Considering the current review, seven cases of IbEL were treated with endograft extension and concomitant hypogastric artery embolization. In one case (14%, 1/7), a buttock claudication, defined as minor, was reported. After distal endograft extension and hypogastric embolization, a reintervention for recurrent IbEL occurred in one case (6%, 1/17).
Also the embolization of IbEL without distal endograft extension has been reported in literature (27%, 8/30). In these cases, different and sometimes multiple materials were placed to cover the endoleak site (e.g. n-BCA, Onyx (ev3 Inc., Irvine, CA)). Two of these patients (25%, 2/8) presented a persistent IbEL during follow-up. Data are scarce, but in our opinion, the sole embolization is not as effective as the distal endograft extension. The reason is that, even if technical success may be achieved during the procedure, an unhealthy iliac artery may dilate over time and the IbEL may reappear. Thus, an adequate distal neck is of vital importance to reduce the risk of IbEL recurrence.
Despite the potential limitations related to the fact that the cases of IbEL reported in non-specific literature (i.e. large case series, where different types of endoleak could not be distinguished) were not included in the analysis, and data about clinical presentation, anatomical characteristics, and follow-up are limited, the current systematic review is the sole study analyzing specifically type IbEL, paving the way for future randomized trials.
Conclusion
To date, specific literature about iliac type IbEL after aorto-iliac endografting for AAA is scant. About 50% of IbEL occurred after six months from the EVAR procedure. Anatomical characteristics such as the length and the diameter of the iliac sealing zone and the tortuosity of the iliac axes seem to play an important role in endoleak formation. These complications are typically managed by endovascular means, and the distal endograft extension (with or without hypogastric embolization) is the most frequent and effective treatment which has been reported in literature.
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